Clinical trials: Apixaban
Atrial Fibrillation
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
- Trial name
- LIBREXIA-AF (NCT05757869)
- Testing
- Milvexian, Apixaban
- Where
- 1,052 sites in United States, Argentina and 37 more
- Volunteers
- 20,284 people
- Sponsor
- Janssen Research & Development, LLC
Atrial Fibrillation, Coronary Artery Disease
Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study
The purpose of the study is to evaluate non-inferiority of oral anticoagulant (OAC) monotherapy to OAC plus single antiplatelet therapy (APT) in patients with atrial fibrillation (AF) and prior (>12 months) coronary stenting.
- Trial name
- OAC-ALONE (NCT01962545)
- Testing
- OAC alone
- Where
- Japan
- Volunteers
- 690 people
- Sponsor
- Satoshi Shizuta
Severe Aortic Valve Stenosis
Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation
The POPular ATLANTIS trial aims to investigate CT-guided antithrombotic therapy compared to lifelong single antiplatelet therapy after a transcatheter aortic valve implantation (TAVI) procedure.
- Trial name
- POP ATLANTIS (NCT06168370)
- Testing
- CT guided strategy
- Where
- Netherlands
- Volunteers
- 2,500 people
- Sponsor
- St. Antonius Hospital
Anticoagulant Therapy
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
DOACs are increasingly used since 8 years. Standard coagulation tests (Prothrombin time [PT] and activated partial thromboplastin time [aPTT]) from plasma samples show a high variation.
- Trial name
- PHAPOCU (NCT05491460)
- Testing
- Apixaban 5 MG Tab, Dabigatran 150 MG Tab, Edoxaban 60Mg Tab
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Doasense GmbH
Venous Thromboembolism
Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter
CV185-079 is a multiple dose Apixaban Pharmacokinetics/Pharmacodynamics (PK/PD) study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects with a central venous…
- Trial name
- NCT01195727
- Testing
- Apixaban
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
Subcutaneous enoxaparin is currently the gold standard for VTE chemoprophylaxis. However, the efficacy of chemoprophylaxis with subcutaneous enoxaparin is affected by patient-level factors, thus, resulting in VTE events despite…
- Trial name
- NCT04504318
- Testing
- Apixaban 2.5 MG Oral Tablet, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Stanford University
Direct Oral Anticoagulants (DOACs), Oral Surgical Procedures
Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)
Direct oral anticoagulants (DOACs) are increasingly used, but evidence on bleeding risk during oral soft tissue biopsy is limited.
- Trial name
- DOACS_BX (NCT07520890)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Healthy Volunteers
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
Background: Rivaroxaban and apixaban are blood thinners. People with HIV may need to take them to treat or prevent blood clots. The anti-HIV drug darunavir (DRV) can increase the amount of these blood thinners in the body.
- Trial name
- NCT03864406
- Testing
- Cobicistat, Darunavir/Cobicistat, Rivaroxaban
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Renal Insufficiency
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic…
- Trial name
- VERDICT (NCT02664155)
- Testing
- Apixaban, Rivaroxaban, Heparin
- Where
- 31 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Hematoma
Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery.
- Trial name
- BRUISECONTROL2 (NCT01675076)
- Testing
- Dabigatran, Rivaroxaban, Apixaban
- Where
- 15 sites in Canada, Israel
- Volunteers
- 663 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Ischemic Stroke, Atrial Fibrillation
Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation
The project is a multicenter, open-label, randomized medical experiment, which was designed to evaluate the efficacy and safety of single-stage pulmonary vein isolation (PVI) and implantation of left atrial appendage occluder…
- Trial name
- PILOS-AF (NCT06212674)
- Testing
- PVI + LAAO, single stage, LAAO, NOAC
- Where
- 2 sites in Poland
- Volunteers
- 240 people
- Sponsor
- Medical University of Silesia
Ischemic Stroke
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute…
- Trial name
- DO-IT (NCT06571149)
- Testing
- Tenecteplase or Alteplase
- Where
- 109 sites in Austria, Belgium and 10 more
- Volunteers
- 906 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrial Fibrillation
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation.
- Trial name
- VALIANT-AF-T (NCT06953726)
- Testing
- Apixaban, Rivaroxaban
- Where
- 9 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- VA Office of Research and Development
Covid19
HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)
HEAL-COVID is jointly Sponsored by Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge. The acute effects of COVID-19 are now well described.
- Trial name
- HEAL-COVID (NCT04801940)
- Testing
- Apixaban, Atorvastatin
- Where
- United Kingdom
- Volunteers
- 2,631 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Cirrhosis, Esophageal and Gastric Varices
Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing…
- Conditions
- Cirrhosis, Esophageal and Gastric Varices, Ascites, Hepatic Encephalopathy
- Trial name
- APIXABAN-PK (NCT07521332)
- Testing
- Apixaban, Carvedilol
- Where
- Pakistan
- Volunteers
- 220 people
- Sponsor
- Asian Institute Of Medical Sciences
COVID-19
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis
- Trial name
- NCT04498273
- Testing
- Apixaban 2.5 MG, Apixaban 5MG, Aspirin
- Where
- 71 sites in United States
- Volunteers
- 657 people
- Sponsor
- Frank C Sciurba
Multiple Myeloma, Total Knee Replacement
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis.
- Trial name
- ProApix (NCT06474182)
- Testing
- Blood sampling, Apixaban
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant…
- Trial name
- ALTERNATIVE (NCT03292666)
- Testing
- Oral Anticoagulant
- Where
- 2 sites in United States
- Volunteers
- 39,603 people
- Sponsor
- University of California, San Francisco
Anticoagulation, Venous Thromboembolism
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay.
- Conditions
- Anticoagulation, Venous Thromboembolism, Atrial Fibrillation
- Trial name
- UniXa (NCT04539301)
- Testing
- Estimated anticoagulant level (conversion factor x anti-Xa activity)
- Where
- France
- Volunteers
- 2,100 people
- Sponsor
- Nantes University Hospital